CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Lipum AB (publ) is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Lipum AB (publ)
Tvistevagen 48C
Phone: +46 903403430p:+46 903403430 UMEA, 907 36  Sweden Ticker: LIPUMLIPUM

Business Summary
Lipum AB (publ) is a Sweden-based biopharmaceutical company specialized in discovery and development of new treatment for chronic inflammatory diseases. Lipum develops new biological medicine for treatment of chronic inflammatory diseases eg rheumatoid arthritis. Development is based on results from preclinical research, for example in well-established animal models for inflammatory arthritis. The prospective drug is an antibody directed against a new target molecule, the protein Bile Salt-Stimulated Lipase (BSSL). Lipum's antibody (SOL-116) has a different mechanism of action than the other drugs. Lipum's drug candidate SOL-116 is a humanized monoclonal antibody and is therefore categorized as a biological drug.
(Source: F-4)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
12/31/202312/31/2022Yes----

General Information
Outstanding Shares: 37,258,740 (As of 4/4/2024)
Stock Exchange: STO
Email Address: info@lipum.se


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, April 23, 2024